# SL12 T-LYMPHOMA: A NEW MODEL FOR GENE CONTROL IN TUMORS

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 1991 · $216,869

## Abstract

Novel cDNA clones were isolated from the SL12.4 murine T-lymphoma cell line
by subtraction hybridization against a sister cell clone which lacks
expression of these genes.  This proposal focuses on the three most
interesting clones which possess unexpected and striking characteristics.
All three are novel in that they have no significant similarity with known
genes or gene products.  They are regulated during embryonic development,
show tissue specific expression in adult animals, and can be induced in
well defined in vitro systems.  One of the novel genes has the hallmarks of
an onco-fetal gene.  Another is expressed only in the T-lymphoid lineage
and the transcripts are strongly induced during T cell activation.  The
third is inducible in SL12.4 cells undergoing maturation and is highly
expressed in ovarian tissues and human ovarian carcinoma cell lines.

Regulation of gene expression.  The regulation of each of the genes will be
examined under inducing and non-inducing conditions, in related and
unrelated lineages, and in somatic cell hybrids formed between expressing
and non-expressing cells.  Rates of transcription will be assessed.  The 5'
regulatory region of each gene will be isolated and tested for function in
transient transfection assays.  In vitro experiments to assess DNA-protein
interactions in the control regions will be examined.
Identification of the protein product.  Studies are proposed to isolate and
characterize the protein products.  One of the genes predicts a protein
with 4 putative transmembrane spanning domains and is likely to be
localized on the cell surface.  The other two likely to be intracellular
proteins.  Antibodies will be prepared against the predicted proteins to
assess the physical properties of the protein, potential glycosylation,
subunit structure and to determine the subcellular localization of each.

Analysis of novel gene expression.  The expression of the genes will be
examined in AKR animals at discrete stages of lymphoma development using a
model system developed by Dr. Esther Hays (who will provide the cells).
Expression of the genes will be examined in selected adult tissue and
during embryogenesis using in situ hybridization.

## Key facts

- **NIH application ID:** 3175590
- **Project number:** 2R01CA037778-07
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **SAM.gov UEI:** UYTTZT6G9DT1
- **Principal Investigator:** Carol L. MacLeod
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1991
- **Award amount:** $216,869
- **Award type:** 2
- **Project period:** 1984-06-15 → 1993-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3175590

## Citation

> US National Institutes of Health, RePORTER application 3175590, SL12 T-LYMPHOMA: A NEW MODEL FOR GENE CONTROL IN TUMORS (2R01CA037778-07). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3175590. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*